| Name | Maxcyte (DI) |
|---|---|
| Epic | MXCT |
| Isin | US57777K1060 |
| Industry |
| Latest share price | 394.00p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £415.41 | Debt ratio | n/a |
| Shares in issue | 105.43 | Debt-to-equity ratio | n/a |
| P/E ratio | n/a | Assets / equity ratio | n/a |
| Total dividends per share | n/a | Price to book value | n/a |
| Dividend yield | n/a | ROCE | -19.25 |
| Dividend cover | n/a | EPS growth | n/a |
| Earning per share | -37 | 52-week high / low | 262.00p / 412.50p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| No dividends declared | |||
| Company name | Maxcyte (DI) |
|---|---|
| Address | MaxCyte, Inc., 9713 Key West Avenue, Ste 400, Rockville, United States, MD 20850 |
| Telephone | +1 (301) 944-1700 |
| Website | http://maxcyte.com/ |
| Director | Position |
|---|---|
| Ms Cynthia Collins | Non-Executive Director |
| Mr Patrick J. Balthrop | Non-Executive Director |
| Mr Richard Douglas | Non-Executive Chairman |
| Mr Art Mandell | Independent Non-Executive Director |
| Ms Rekha Hemrajani | Independent Non-Executive Director |
| Mr Stan Erck | Independent Non-Executive Director |
| Mr John Johnston | Independent Non-Executive Director |
| Dr Yasir Al Wakeel | Independent Non-Executive Director |
| Mr Will Brooke | Independent Non-Executive Director |
| Mr Maher Masoud | President and CEO |
| Assets $ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Reporting date | 31/12/23 | 31/12/22 | 31/12/21 |
| Intangible asssets and goodwill | n/a | n/a | n/a |
| Investments and other non-current assets | 42.94 | n/a | n/a |
| Total non-current assets | 78.08 | 34.39 | 13.69 |
| Inventory / work in progress | 12.23 | 8.58 | 5.2 |
| Trade and other receivables | 9.68 | 16.35 | 10.18 |
| Cash and equivalents | 46.51 | 11.06 | 47.78 |
| Other current assets and asset held for resale | n/a | n/a | n/a |
| Total of all assets | 268.27 | 286.65 | 284.12 |
| Liabilities $ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Short term liabilities | 17.85 | 15.43 | 15.62 |
| Long term liabilities | 18.25 | 17.26 | 5.61 |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 36.11 | 32.69 | 21.22 |
| Net assets $ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Net assets | 232.17 | 253.97 | 262.9 |
| Equity $ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Share capital | 1.04 | 1.02 | 1.01 |
| Minority interests | n/a | n/a | n/a |
| Retained earnings | -175.8 | -137.88 | -114.3 |
| Share premium account | 406.92 | 390.82 | n/a |
| Total equity | 232.17 | 253.97 | 262.9 |
| Income $ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | -48.3 | -27.36 | -18.19 |
| Pre-tax profit | -37.92 | -23.57 | -19.08 |